Buy Ketas (ibudilast). Ketas (ibudilast) is a medicine for treating asthma and brain and blood vessel disorders. It helps with dizziness after a stroke.
It comes in capsule form, with 10 mg ibudilast in each.
Ibudilast is also being studied for treating ALS. It has orphan drug status from the EMA and FDA for this purpose.
Ketas (ibudilast) is for people with asthma or brain and blood vessel disorders. It’s especially helpful for those with dizziness after strokes.
It should be used carefully by certain patients. This includes those in the early stages of brain attacks, those with liver problems, and the elderly.
It doesn’t stop asthma attacks right away. Patients on long-term asthma treatments should slow down steroid use under doctor’s watch.
Since 2016, ibudilast has orphan drug status for ALS. The ongoing trial is called MN-166.
Note: This means the medicine has not yet been approved by the EMA or the FDA. But because ALS is so serious, it gets special treatment from these agencies.
Ketas (ibudilast) works by blocking phosphodiesterase enzymes. This has several effects.
It makes airways wider, blood vessels wider, protects brain parts, and reduces inflammation.
The EMA says ibudilast’s exact effect on ALS is not fully understood. It’s thought to block certain brain cell functions. This could slow down inflammation and boost protective molecules. It also reduces activity of certain brain cells involved in ALS.
Ketas (ibudilast) is approved for asthma and brain and blood vessel disorders by:
Ibudilast got orphan drug status for ALS from the EMA and FDA in 2016.
Note: This means the medicine has not been approved by the EMA or the FDA. But because ALS is so serious, it gets special treatment from these agencies.
Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.
Please be aware that any decision to use a prescription generic or brand name medicine should always be taken in consultation with a medical professional. The FDA has sent warning letters to drugmakers in India or Pakistan concerning the quality of their medicines.
The standard dosage is:
Warning: In the case of cerebral infarction, periods during which Ketas (ibudilast) is given should be decided carefully, taking into account how effective it is, as well as adverse reactions. If the expected effects of the medicine are not observed after 12 weeks of taking it, the medicine should be discontinued.
Complete information about Ketas (ibudilast) dosage and administration can be found in the official prescribing information listed below.
Note: Please consult with your treating doctor for personalised dosing.
The most common adverse reactions listed in the prescribing information include:
The serious adverse reactions listed in the prescribing information include:
Ketas (ibudilast) is metabolised mainly by the liver. Because there is a possibility of high blood concentration in elderly patients, who often have liver hypofunction (reduced, low or inadequate function), this medicine should be given with caution and special attention to elderly patients.
Ketas (ibudilast) is not recommended for use in pregnant women or women who are breastfeeding.
The safety of this product in children has not yet been tested.
Optimized by Seraphinite Accelerator